Regulation of excitatory neural input to longitudinal intestinal muscle by myenteric interneurons.
The circuit of myenteric interneurons that regulate excitatory input to longitudinal colonic muscle was identified using dispersed ganglia and longitudinal muscle strips with adherent myenteric plexus from rat distal colon. The preparations enabled measurement of neurotransmitter release from interneurons and/or excitatory motoneurons innervating longitudinal muscle. 1, 1-Dimethyl-4-phenylpiperizinium (DMPP) and somatostatin were used to activate myenteric neurons in dispersed ganglia and muscle strips, respectively. DMPP-stimulated vasoactive intestinal peptide (VIP) release in dispersed ganglia was inhibited by [Met]enkephalin and bicuculline and augmented by naloxone and GABA, implying that inhibitory opioid and stimulatory GABA neurons regulate the activity of VIP interneurons. In muscle strips, VIP stimulated basal and augmented somatostatin-induced substance P (SP) release; the somatostatin-induced increase in SP release was inhibited by VIP-(10-28) and NG-nitro-L-arginine, implying that excitatory VIP neurons regulate tachykinin motoneurons innervating longitudinal muscle. Somatostatin inhibited [Met]enkephalin and stimulated VIP release; basal and somatostatin-stimulated VIP release were inhibited by [Met]enkephalin and bicuculline and augmented by naloxone and GABA, implying that inhibitory pathways linking somatostatin, opioid, and GABA neurons regulate VIP interneurons, which in turn regulate tachykinin and probably cholinergic motoneurons.
Grider
J R
JR
Departments of Physiology and Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0551, USA.
D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D003106:Colon / Q000502:physiology*; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D004744:Enkephalin, Methionine / Q000378:metabolism / Q000494:pharmacology; D005725:Ganglia, Autonomic / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D007395:Interneurons / Q000187:drug effects / Q000502:physiology*; D008959:Models, Neurological; D009130:Muscle, Smooth / Q000502:physiology*; D009197:Myenteric Plexus / Q000502:physiology*; D009270:Naloxone / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009569:Nitric Oxide / Q000494:pharmacology; D019335:Nitroarginine / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D013004:Somatostatin / Q000494:pharmacology / Q000502:physiology; D013373:Substance P / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D018377:Neurotransmitter Agents; D010446:Peptide Fragments; D019335:Nitroarginine; D009569:Nitric Oxide; D013373:Substance P; D009270:Naloxone; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D004246:Dimethylphenylpiperazinium Iodide; D005680:gamma-Aminobutyric Acid; D004744:Enkephalin, Methionine; C047945:vasoactive intestinal peptide (10-28); D001640:Bicuculline